Radiotherapy in African Cancer Centers: Current Status & Expansion Plans 2024
This article discusses the advancements and expansion plans for radiotherapy in African cancer centers, highlighting the need for improved cancer treatment options.
Quick Answer
This article discusses the advancements and expansion plans for radiotherapy in African cancer centers, highlighting the need for improved cancer treatment options.
Key Questions
- What is the current state of radiotherapy access in Africa?
- What role does SAHPRA play in radiotherapy equipment approval?
- What advanced radiotherapy technologies are being implemented in Africa?
- What is the IAEA Rays of Hope initiative?
- What are the workforce requirements for radiotherapy expansion by 2050?
The Middle East and Africa (MEA) radiotherapy market reached $362 million in 2024 and is projected to grow to $655 million by 2032. WHO data shows 1.18 million new cancer cases in Africa annually, yet IAEA reports over 70% of the continent's population lacks access to radiotherapy. SAHPRA regulates equipment imports under South Africa's Hazardous Substances Act, while the IAEA's Rays of Hope initiative supports capacity expansion.
Contents9 sections
Key Takeaways
- Market expansion: The MEA radiotherapy market is valued at $362.38 million in 2024, projected to reach $655.69 million by 2032 (industry analysis).
- Access gap: IAEA data shows over 70% of Africa's population lacks radiotherapy access, despite radiation therapy treating over half of all cancer patients globally.
- Cancer burden: WHO GLOBOCAN 2022 reports 1.18 million new cancer cases and 763,843 deaths annually in Africa.
- Regulatory framework: SAHPRA's December 2023 guidelines establish licensing requirements for radiotherapy equipment imports under South Africa's Hazardous Substances Act 15 of 1973.
- Workforce needs: The IAEA-led Lancet Oncology Commission (September 2024) projects the global radiotherapy workforce must expand 60% by 2050 to meet demand.
What Is the Current Cancer Burden in Africa?
Cancer now rivals infectious diseases as a leading cause of death across the African continent. WHO GLOBOCAN 2022 data documents 1,185,216 new cancer cases annually in Africa, with 763,843 deaths and 2.6 million five-year prevalent cases. Breast cancer leads among women; prostate cancer tops the list for men.
The WHO identifies cancer as a leading cause of death worldwide, accounting for nearly 10 million deaths in 2024. Cervical cancer remains the most common cancer among women in 26 countries—primarily in sub-Saharan Africa. This epidemiological profile underscores the urgent need for expanded treatment infrastructure.
Why Does Radiotherapy Access Remain Limited in Africa?
The gap between cancer burden and treatment capacity is stark. IAEA's Rays of Hope initiative reports that over 70% of Africa's population lacks access to radiotherapy services. This is particularly critical given that radiation therapy is fundamental for treating over half of all cancer patients. African countries face the greatest shortage.
Multiple factors drive this disparity. Capital costs for linear accelerators and brachytherapy units exceed many national health budgets. Specialized workforce shortages compound the equipment gap. Training radiation oncologists, medical physicists, and radiotherapy technologists requires years of education. Maintenance and technical support remain limited in resource-constrained settings.
The consequences are measurable. Patients face delayed diagnoses, incomplete treatment courses, and poor cancer outcomes. Addressing these gaps demands coordinated investment from government health agencies, international organizations, and private sector partners.
What Advanced Radiotherapy Technologies Are African Centers Adopting?
African cancer centers are progressively deploying advanced radiotherapy modalities. These include:
- Intensity-modulated radiotherapy (IMRT): Delivers conformal dose distributions while sparing healthy tissue
- Stereotactic body radiotherapy (SBRT): Enables high-dose, hypofractionated treatment in fewer sessions
- Hypofractionated radiotherapy: Shortens treatment duration and may reduce costs and improve completion rates
- Proton therapy: Provides superior dose deposition with reduced distal toxicity
- Adaptive radiotherapy: Adjusts treatment plans based on anatomical changes during therapy
The Uganda Cancer Institute exemplifies this trend. The institute is conducting a Phase II randomized non-inferiority trial (NCT07276360) comparing hypofractionated radiotherapy (40 Gy in 16 fractions) to conventional fractionated radiotherapy (45 Gy in 25 fractions) for locally advanced cervical cancer. Collaborators include Varian Medical Systems and the Fogarty International Center of the U.S. National Institutes of Health. The trial started March 11, 2026, with primary completion expected January 2, 2028.
How Does SAHPRA Regulate Radiotherapy Equipment?
The South African Health Products Regulatory Authority (SAHPRA) provides regulatory oversight for radiotherapy equipment imports and deployment. SAHPRA's December 2023 guidelines establish licensing requirements for electronic devices emitting ionizing radiation under South Africa's Hazardous Substances Act 15 of 1973.
The guidelines require:
- Registration with the Companies and Intellectual Property Commission
- Comprehensive technical files including manufacturer documentation
- Radiation safety assessments
- Device-specific import license applications
SAHPRA's framework serves as a regional reference for radiotherapy equipment regulation. However, harmonization across MEA countries remains incomplete. This creates regulatory complexity for manufacturers and healthcare providers seeking to expand across borders.
What Workforce Expansion Is Needed by 2050?
The IAEA-led Lancet Oncology Commission on Radiotherapy and Theranostics, published September 2024, surveyed 200 radiotherapy centers across 55 countries. The findings are sobering: the 2022 radiotherapy workforce must expand by over 60% by 2050 to meet projected cancer demand.
Global workforce requirements by 2050 include:
| Role | Projected Need by 2050 |
|---|---|
| Radiation oncologists | 84,000 |
| Medical physicists | 47,000 |
| Radiotherapy technologists | 141,000 |
The Commission identifies mitigation strategies including workflow optimization, resource-sparing approaches, and hypofractionation adoption. At 50% substitution rates, hypofractionated radiotherapy could generate $1.28 billion in cost savings for prostate cancer and $1.48 billion for breast cancer globally.
What Is the IAEA Rays of Hope Initiative?
The IAEA Rays of Hope initiative addresses the stark disparity in cancer care access between high-income and low- and middle-income countries. The initiative recognizes that survival chances depend heavily on geographic location, with many LMIC populations lacking access to life-saving diagnostic and treatment services.
Key priorities include:
- Building national cancer control program capacity
- Expanding radiotherapy infrastructure and equipment
- Training specialized workforce in radiation medicine
- Supporting quality assurance and safety programs
The initiative operates within the broader WHO-IAEA Joint Programme on Cancer Control, coordinating with national ministries of health and international partners to strengthen the full cancer care continuum—from prevention and early detection through treatment and palliative care.
Frequently Asked Questions
What is the current state of radiotherapy access in Africa?
Over 70% of Africa's population lacks access to radiotherapy, according to IAEA data. The WHO reports 1.18 million new cancer cases in Africa annually. The MEA radiotherapy market is valued at $362 million in 2024, with projections reaching $655 million by 2032.
What role does SAHPRA play in radiotherapy equipment approval?
The South African Health Products Regulatory Authority (SAHPRA) regulates radiotherapy equipment imports under South Africa's Hazardous Substances Act 15 of 1973. SAHPRA's December 2023 guidelines establish licensing requirements and technical documentation standards for electronic devices emitting ionizing radiation.
What advanced radiotherapy technologies are being implemented in Africa?
African cancer centers are adopting intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), proton therapy, and hypofractionated radiotherapy. The Uganda Cancer Institute is conducting a Phase II trial (NCT07276360) comparing hypofractionated radiotherapy to conventional fractionated treatment for cervical cancer, with support from Varian Medical Systems and the Fogarty International Center.
What is the IAEA Rays of Hope initiative?
The IAEA Rays of Hope initiative helps low- and middle-income countries increase access to cancer care. Radiation therapy treats over half of all cancer patients, yet over 70% of Africa's population lacks access. The initiative supports capacity building in cancer diagnosis, staging, and treatment.
What are the workforce requirements for radiotherapy expansion by 2050?
The IAEA-led Lancet Oncology Commission on Radiotherapy and Theranostics (September 2024) projects that the 2022 radiotherapy workforce must expand by over 60% by 2050. This requires 84,000 radiation oncologists, 47,000 medical physicists, and 141,000 radiotherapy technologists globally to meet rising cancer demand.
Primary Sources
- World Health Organization. Cancer Fact Sheet. 2024. https://www.who.int/news-room/fact-sheets/detail/cancer
- International Agency for Research on Cancer. GLOBOCAN 2022: Africa Fact Sheet. WHO; 2024. https://gco.iarc.who.int/media/globocan/factsheets/populations/903-africa-fact-sheet.pdf
- International Atomic Energy Agency. Rays of Hope: Cancer Care For All. IAEA Bulletin; 2022. https://www.iaea.org/bulletin/rays-of-hope
- IAEA Lancet Oncology Commission on Radiotherapy and Theranostics. Expanding global radiotherapy access 2024. Published September 2024. https://www.iaea.org/topics/comprehensive-cancer-control/lancet-oncology-commission-on-radiotherapy-and-theranostics
- South African Health Products Regulatory Authority. Guideline for Import Applications of Electronic Devices Emitting Ionizing Radiation. December 2023. https://www.sahpra.org.za/wp-content/uploads/2024/01/SAHPGL-RDN-XR-24_v1.pdf
- ClinicalTrials.gov. Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda. NCT07276360. https://clinicaltrials.gov/study/NCT07276360
This article follows our editorial standards. Report a correction via editorial contact.
Continue Your Research
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…